Literature DB >> 1657373

Expression of the c-Ha-ras oncogene in mouse NIH 3T3 cells induces resistance to cisplatin.

S Isonishi1, D K Hom, F B Thiebaut, S C Mann, P A Andrews, A Basu, J S Lazo, A Eastman, S B Howell.   

Abstract

The effect of expression of the c-Ha-ras oncogene on cisplatin (DDP) sensitivity was examined in murine NIH 3T3 cells transfected with the dexamethasone (DEX)-inducible mouse mammary tumor virus promoter linked to an activated c-Ha-ras gene [LTR H-ras(A) cells]. Treatment of these cells with 5 microM DEX for 24 h induced c-Ha-ras expression and produced an 8.2 +/- 1.3-fold (SD) increase in DDP resistance as quantitated by clonogenic assay. Induction of the c-Ha-ras oncogene reduced DDP accumulation by 40% and intrastrand adduct formation by 17%. In nontransfected wild-type NIH 3T3 cells, DEX did not induce DDP resistance nor did it decrease DDP accumulation. Induction of c-Ha-ras expression did not alter cellular glutathione content or the activity of glutathione-S-transferase in the LTR H-ras(A) cells. DEX increased cellular metallothionein content by 1.6-fold in NIH 3T3 cells and 3.3-fold in LTR H-ras(A) cells. We conclude that DEX-induced overexpression of a mutant c-Ha-ras gene confers DDP resistance and that this resistance is associated with an impairment of cellular drug accumulation and an increase in metallothionein content.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1657373

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Restricted 12p amplification and RAS mutation in human germ cell tumors of the adult testis.

Authors:  H Roelofs; M C Mostert; K Pompe; G Zafarana; M van Oorschot; R J van Gurp; A J Gillis; H Stoop; B Beverloo; J W Oosterhuis; C Bokemeyer; L H Looijenga
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

Review 2.  Potential roles for prions and protein-only inheritance in cancer.

Authors:  H Antony; A P Wiegmans; M Q Wei; Y O Chernoff; K K Khanna; A L Munn
Journal:  Cancer Metastasis Rev       Date:  2012-06       Impact factor: 9.264

Review 3.  Are RAS mutations predictive markers of resistance to standard chemotherapy?

Authors:  Yohann Loriot; Pierre Mordant; Eric Deutsch; Ken André Olaussen; Jean-Charles Soria
Journal:  Nat Rev Clin Oncol       Date:  2009-07-14       Impact factor: 66.675

4.  Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu.

Authors:  C C Benz; G K Scott; J C Sarup; R M Johnson; D Tripathy; E Coronado; H M Shepard; C K Osborne
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

5.  Lentiviral short hairpin RNA screen of genes associated with multidrug resistance identifies PRP-4 as a new regulator of chemoresistance in human ovarian cancer.

Authors:  Zhenfeng Duan; Edward J Weinstein; Diana Ji; Rachel Y Ames; Edwin Choy; Henry Mankin; Francis J Hornicek
Journal:  Mol Cancer Ther       Date:  2008-08-07       Impact factor: 6.261

6.  Mutagenesis in monkey cells of a vector containing a single d(GPG) cis-diamminedichloroplatinum(II) adduct placed on codon 13 of the human H-ras proto-oncogene.

Authors:  M J Pillaire; A Margot; G Villani; A Sarasin; M Defais; A Gentil
Journal:  Nucleic Acids Res       Date:  1994-07-11       Impact factor: 16.971

Review 7.  Signaling and drug sensitivity.

Authors:  R D Christen; S Isonishi; J A Jones; A P Jekunen; D K Hom; R Kröning; D P Gately; F B Thiebaut; G Los; S B Howell
Journal:  Cancer Metastasis Rev       Date:  1994-06       Impact factor: 9.264

8.  Molecular characterization of the in vivo alkylating agent resistant murine EMT-6 mammary carcinoma tumors.

Authors:  D Chatterjee; C J Liu; D Northey; B A Teicher
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 9.  Human cell lines as models for multidrug resistance in solid tumours.

Authors:  M Clynes; M Heenan; K Hall
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

Review 10.  Role of protein kinases in antitumor drug resistance.

Authors:  H Grunicke; J Hofmann; I Utz; F Uberall
Journal:  Ann Hematol       Date:  1994       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.